Literature DB >> 7780097

Distribution and characterization of beta-lactamases of mycobacteria and related organisms.

H H Kwon1, H Tomioka, H Saito.   

Abstract

SETTING: The detailed distribution and precise features of mycobacterial beta-lactamases urgently need to be elucidated.
OBJECTIVE: To study the distribution pattern of beta-lactamases among mycobacteria, their enzymatic profiles and degree of contribution to the expression of drug resistance of some mycobacteria to beta-lactam antibiotics.
DESIGN: Cell-associated beta-lactamase was measured by nitrocefin disc method. beta-lactamases obtained from some mycobacteria were studied for their substrate specificity, metal ion-dependency and isoelectric focusing (IEF) patterns. Changes in the minimum inhibitory concentrations (MICs) of beta-lactams for rapidly growing mycobacteria due to the combined use of tazobactam were measured.
RESULTS: In slow growers, Mycobacterium tuberculosis complex possessed strong and M. kansasii showed strong to intermediate beta-lactamase activity, while M. avium complex lacked such an activity. All the rapid growers possessed strong to intermediate activity. The beta-lactamases of test organisms including M. tuberculosis, M. kansasii, M. fortuitum etc, exerted both penicillinase and cephalosporinase activities and were not metalloenzymes. M. tuberculosis, M. kansasii, and M. smegmatis exhibited the species-specific IEF patterns of beta-lactamases. Tazobactam potentiated the in vitro antimicrobial activities of some beta-lactams against M. fortuitum and M. chelonae.
CONCLUSION: Many mycobacteria possessed peculiar beta-lactamases and the enzymes were partly attributable to their drug resistance to certain beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780097     DOI: 10.1016/0962-8479(95)90557-x

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  17 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

3.  Predicting the in vivo mechanism of action for drug leads using NMR metabolomics.

Authors:  Steven Halouska; Robert J Fenton; Raúl G Barletta; Robert Powers
Journal:  ACS Chem Biol       Date:  2011-12-01       Impact factor: 5.100

4.  Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Authors:  C J Hackbarth; I Unsal; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Rapid and specific labeling of single live Mycobacterium tuberculosis with a dual-targeting fluorogenic probe.

Authors:  Yunfeng Cheng; Jinghang Xie; Kyung-Hyun Lee; Rajiv L Gaur; Aiguo Song; Tingting Dai; Hongjun Ren; Jiannan Wu; Zhaogang Sun; Niaz Banaei; Demir Akin; Jianghong Rao
Journal:  Sci Transl Med       Date:  2018-08-15       Impact factor: 17.956

6.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  C Segura; M Salvadó; I Collado; J Chaves; A Coira
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe.

Authors:  Hexin Xie; Joseph Mire; Ying Kong; MiHee Chang; Hany A Hassounah; Chris N Thornton; James C Sacchettini; Jeffrey D Cirillo; Jianghong Rao
Journal:  Nat Chem       Date:  2012-09-02       Impact factor: 24.427

9.  The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds.

Authors:  Simon J Waddell; Richard A Stabler; Ken Laing; Laurent Kremer; Robert C Reynolds; Gurdyal S Besra
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

Review 10.  The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

Authors:  A Somoskovi; L M Parsons; M Salfinger
Journal:  Respir Res       Date:  2001-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.